Published in Eur J Cancer on November 28, 2011
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol (2015) 1.65
STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun (2015) 1.63
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 1.26
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19
Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol (2013) 1.07
Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res (2013) 0.97
Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol (2015) 0.97
Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets (2012) 0.95
Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues. Mol Cancer Res (2013) 0.94
Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resist Updat (2014) 0.92
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) (2014) 0.91
The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol (2013) 0.91
B-lymphocyte lineage cells and the respiratory system. J Allergy Clin Immunol (2013) 0.89
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am J Clin Exp Urol (2014) 0.87
Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol (2013) 0.87
The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol (2013) 0.86
MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov (2015) 0.85
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer (2015) 0.85
Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol (2015) 0.84
Retracted Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev (2015) 0.84
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs (2014) 0.84
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther (2014) 0.84
Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells. Oncol Lett (2015) 0.80
Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents. Evid Based Complement Alternat Med (2014) 0.79
A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. Cancer Immunol Res (2015) 0.78
Proinflammatory and Anti-Inflammatory Cytokines Mediated by NF-κB Factor as Prognostic Markers in Mammary Tumors. Mediators Inflamm (2016) 0.77
Proinflammatory cytokines in prostate cancer development and progression promoted by high-fat diet. Biomed Res Int (2015) 0.77
Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther (2014) 0.77
Siltuximab (CNTO 328): a promising option for human malignancies. Drug Des Devel Ther (2015) 0.76
The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer. Cancer Growth Metastasis (2013) 0.76
Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget (2015) 0.75
Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. Oncoimmunology (2015) 0.75
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. Cancers (Basel) (2017) 0.75
Interleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1α regulation. Oncol Lett (2016) 0.75
Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy. PLoS One (2017) 0.75
IL-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci (2017) 0.75
Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Semin Cancer Biol (2017) 0.75
Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. Target Oncol (2017) 0.75
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Slow conduction in the infarcted human heart. 'Zigzag' course of activation. Circulation (1993) 3.13
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol (2013) 2.41
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Planning the human variome project: the Spain report. Hum Mutat (2009) 2.22
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol (2011) 2.15
Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res (2013) 2.02
Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. J Cardiovasc Electrophysiol (2003) 1.91
Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation (2012) 1.89
EAU guidelines on prostate cancer. Eur Urol (2005) 1.88
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther (2008) 1.88
Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome. J Cardiovasc Electrophysiol (2006) 1.88
Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol (2009) 1.81
Long-QT syndrome after age 40. Circulation (2008) 1.73
Long QT syndrome and pregnancy. J Am Coll Cardiol (2007) 1.71
A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose. Clin Toxicol (Phila) (2010) 1.68
A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet (2013) 1.66
Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64
Sacral colpopexy with concurrent Burch colposuspension in patients with vaginal vault prolapse. Urol Int (2006) 1.60
Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol (2011) 1.59
Dispersion of 'refractoriness' in noninfarcted myocardium of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Circulation (1995) 1.55
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol (2010) 1.53
Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol (2003) 1.53
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
Prognostic implications of mutation-specific QTc standard deviation in congenital long QT syndrome. Heart Rhythm (2013) 1.46
Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer (1998) 1.46
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Fractionated electrograms in dilated cardiomyopathy: origin and relation to abnormal conduction. J Am Coll Cardiol (1996) 1.44
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44
Identification of sequence variants in genetic disease-causing genes using targeted next-generation sequencing. PLoS One (2011) 1.44
Focal therapy in prostate cancer-report from a consensus panel. J Endourol (2010) 1.43
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.43
[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]. Aktuelle Urol (2006) 1.42
Atrioventricular junctional tissue. Discrepancy between histological and electrophysiological characteristics. Circulation (1996) 1.41
Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation. Circ Cardiovasc Genet (2011) 1.40
Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol (1994) 1.39
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer (2008) 1.37
Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol (2005) 1.31
Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. Nat Genet (2012) 1.31
Coagulopathy in prostate cancer. Neth J Med (2003) 1.29
Influence of injection site, microvascular pressure and ultrasound variables on microbubble-mediated delivery of microspheres to muscle. J Am Coll Cardiol (2002) 1.25
Bone mineral density and its change in pre-and perimenopausal white women: the Michigan Bone Health Study. J Bone Miner Res (1998) 1.22
alpha-1-syntrophin mutation and the long-QT syndrome: a disease of sodium channel disruption. Circ Arrhythm Electrophysiol (2008) 1.19
Dispersion of refractoriness in canine ventricular myocardium. Effects of sympathetic stimulation. Circ Res (1991) 1.19
Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res (1996) 1.16
Giant calculus of the posterior urethra following recurrent penile urethral stricture. Urol Int (2002) 1.16
Morphology of electrophysiologically identified junctions between Purkinje fibers and ventricular muscle in rabbit and pig hearts. Circ Res (1991) 1.14
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Origin and significance of double potentials near the atrioventricular node. Correlation of extracellular potentials, intracellular potentials, and histology. Circulation (1994) 1.12
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2011) 1.11
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol (2008) 1.11
Capturing all disease-causing mutations for clinical and research use: toward an effortless system for the Human Variome Project. Genet Med (2009) 1.10
Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol (2010) 1.06
Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease. Cancer (1997) 1.05
Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta (1998) 1.02
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res (1994) 1.01
Stimulation of arteriogenesis in skeletal muscle by microbubble destruction with ultrasound. Circulation (2002) 1.01
Recommendations for genetic variation data capture in developing countries to ensure a comprehensive worldwide data collection. Hum Mutat (2011) 0.99
Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK. J Cell Biochem (2011) 0.98
Long QT syndrome in patients over 40 years of age: increased risk for LQTS-related cardiac events in patients with coronary disease. Ann Noninvasive Electrocardiol (2008) 0.98
Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology (2011) 0.96
Novel compound heterozygous mutations in the KCNQ1 gene associated with autosomal recessive long QT syndrome (Jervell and Lange-Nielsen syndrome). Ann Noninvasive Electrocardiol (2003) 0.95
Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity. J Cell Physiol (2009) 0.94
Local recurrence of an oncocytic adrenocortical carcinoma with ovary metastasis. J Urol (2001) 0.93
Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography. Ann Neurol (1998) 0.93
Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonists. Am J Cardiol (2008) 0.93
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs (2001) 0.91
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs (2012) 0.91
Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer (2009) 0.91
Changes in sinus node function in a rabbit model of heart failure with ventricular arrhythmias and sudden death. Circulation (2000) 0.90
[European Association of Urology guidelines on urinary and male genital tract infections]. Urologe A (2003) 0.89
Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer (2001) 0.89
Interaction of sympathetic and parasympathetic nervous system on ventricular refractoriness assessed by local fibrillation intervals in the canine heart. Cardiovasc Res (1993) 0.88
Cellular uncoupling during ischemia in hypertrophied and failing rabbit ventricular myocardium: effects of preconditioning. Circulation (1998) 0.87
Dispersion of refractoriness in normal and ischaemic canine ventricle: effects of sympathetic stimulation. Cardiovasc Res (1993) 0.87
A clinical and molecular-genetic analysis of Chinese patients with lattice corneal dystrophy and novel Thr538Pro mutation in the TGFBI (BIGH3) gene. J Genet (2006) 0.87
Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: results of a prospective randomized trial. J Urol (2003) 0.86
Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J Cell Physiol (2009) 0.86
p.Ala546 > Asp and p.Arg555 > Trp mutations of TGFBI gene and their clinical manifestations in two large Chinese families with granular corneal dystrophy type I. Genet Test (2008) 0.86
[Isolated epididymal torsion in dissociation of testis-epididymis]. Urologe A (2002) 0.86
PCR detection of Epstein-Barr virus, herpes simplex virus and human papillomavirus from the anal mucosa in HIV-seropositive and HIV-seronegative homosexual men. Int J STD AIDS (1999) 0.85
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Actas Urol Esp (2011) 0.85
[Guidelines for German urologists on diagnosis of benign prostate syndrome]. Urologe A (2003) 0.85
Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome. J Cardiovasc Electrophysiol (2009) 0.85
The prevalence of "high-risk" HPV types in penile condyloma-like lesions: correlation between HPV type and morphology. Genitourin Med (1993) 0.85
Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Br J Cancer (2001) 0.85
A Chinese patient with KBG syndrome and a 9q31.2-33.1 microdeletion. Eur J Med Genet (2013) 0.84
Correlation between cognitive function and the association fibers in patients with Alzheimer's disease using diffusion tensor imaging. J Clin Neurosci (2012) 0.84
LQTS gene LOVD database. Hum Mutat (2010) 0.84
[Metastasectomy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors]. Urologe A (2012) 0.84